Gilead Sciences, Inc. (NASDAQ:GILD) NASDAQ 47th Investor Conference December 7, 2022 8:00 AM ET Company Participants Dan O'Day - Chairman and CEO Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison All right. Perfect. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts at Morgan Stanley. Really pleased to have Dan O'Day, the Chairman and CEO at Gilead with us. Just a reminder, personal analyst holding disclosures are available on morganst ...

Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler Healthcare Conference November 30, 2022 11:30 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Do Kim - Piper Sandler Do Kim All right. Good morning. And thank you, everyone for joining us for our next company presentation. My name is Do Kim. I am one of the Senior Biotech Analysts here at Piper. And we have with us Gilead, and it's my pleasure to welcome CMO, Merdad Parsey. Merdad, thank you for being here. Merda ...

Gilead Sciences, Inc. (NASDAQ:GILD) 2022 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 1:00 PM ET Company Participants Andrew Dickinson - Executive Vice President & Chief Financial Officer William Grossman - Senior Vice President of Oncology Clinical Research Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Umer Raffat Excellent. Thank you guys for joining us. We have tons to review today. Thank you Andy and Bill for joining us. And it' ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O’Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - CFO Christi Shaw - CEO, Kite Conference Call Participants Chris Schott - JPM Salveen Richter - Goldman Sachs Brian Abrahams - RBC Michael Yee - Jefferies Brian Skorney - Baird Matthew Harrison - Morgan Stanley Tyler Van Buren - Cowen Umer Ra ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird 2022 Global Healthcare Conference September 14, 2022 9:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney Good morning, everyone. Thank you for joining us our next fireside chat. I'm really pleased to have with me the Chief Commercial Officer of Gilead Sciences, Johanna Mercier. Gilead is a name I'm sure everyone is familiar with. It's one of the bellwethers of the sector, a long- ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:35 AM ET Company Participants Daniel O'Day - Chairman & CEO William Grossman - SVP, Oncology Clinical Development Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison I think we're ready. So good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Gilead with u ...

Gilead Sciences, Inc. (NASDAQ:GILD) 2022 Wells Fargo Healthcare Conference September 8, 2022 10:25 AM ET Company Participants Andrew Dickinson - CFO Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. Thank you very much for this session. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo. And with us, we have Andy, the CFO of Gilead. Thank you very much, Andy, for joining us. Andrew Dickinson Thank you for having us. Happy to be here. Question-and-Answer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ...

Gilead Science's second quarter 2022 earnings conference call. All lines have been placed on mute to prevent background noises. After today's remarks, there will be a question and answer session. If you would like to ask a question, please press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star followed by two. Please be advised that today's call is being recorded. I would now like to hand the conference over to Jackie Ross Vice President of In ...